Alzamend Neuro (Nasdaq:ALZN) - 주가, 뉴스 및 분석

ALZN 주식 개요

임상 단계의 바이오 제약 회사인 알자멘드 뉴로는 신경 퇴행성 및 정신과 질환 치료를 위한 다양한 제품 개발에 주력하고 있습니다. 자세한 내용

ALZN 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

위험 분석

마이너스 주주 지분

수익은 향후 3년간 연평균 38% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

+ 2 더 많은 위험

Alzamend Neuro, Inc. 경쟁사

Ainos

NasdaqCM:AIMD

US$6.4m

Xenetic Biosciences

NasdaqCM:XBIO

US$6.3m

Organovo Holdings

NasdaqCM:ONVO

US$6.6m

Aptinyx

OTCPK:APTX

US$6.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Alzamend Neuro
과거 주가
현재 주가	US$1.27
52주 최고치	US$15.06
52주 최저치	US$1.25
베타	-0.038
11개월 변경	-22.39%
3개월 변경 사항	-44.76%
1년 변경 사항	-89.19%
33년 변화	-99.57%
5년 변화	n/a
IPO 이후 변화	-99.94%

최근 뉴스 및 업데이트

Recent updates

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

주주 수익률

	ALZN	US Biotechs	US 마켓
7D	-3.4%	4.3%	1.6%
1Y	-89.2%	18.8%	32.3%

수익률 대 산업: ALZN 지난 1년 동안 18.8 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ALZN 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ALZN's price volatile compared to industry and market?
ALZN volatility
ALZN Average Weekly Movement	8.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: ALZN 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ALZN 의 주간 변동성은 지난 1년 동안 29% 에서 8% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2016	6	Stephan Jackman	www.alzamend.com

임상 단계의 바이오 제약 회사인 알자멘드 뉴로는 신경 퇴행성 및 정신 질환 치료를 위한 다양한 제품을 개발하는 데 주력하고 있습니다. 알츠하이머, 양극성 장애, 외상 후 스트레스 장애, 주요 우울 장애, 기타 신경 퇴행성 질환 및 정신 장애 치료를 위한 리튬, 프롤린 및 살리실레이트의 치료 조합을 제공하는 AL001과 알츠하이머병에 대항하는 환자의 면역 체계의 능력을 회복시키기 위해 세포 기반 치료 백신으로 변이 펩티드 민감화 세포를 사용하는 방법을 사용하는 ALZN002 단계를 포함한 파이프라인을 보유하고 있습니다. 이 회사는 AL001의 임상 2상 시험을 위해 매사추세츠 종합병원과 파트너십 계약을 체결했습니다.

Alzamend Neuro, Inc. 기본 사항 요약

Alzamend Neuro 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ALZN 기본 통계
시가총액	US$5.75m
수익(TTM)	-US$7.39m
수익(TTM)	n/a

0.0x

P/S 비율

-0.8x

P/E 비율

ALZN 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ALZN 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$7.39m
수익	-US$7.39m

최근 보고된 수익

Jul 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.65
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ALZN 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ALZN 주식 개요

위험 분석

Alzamend Neuro, Inc. 경쟁사

NasdaqCM:AIMD

US$6.4m

NasdaqCM:XBIO

US$6.3m

NasdaqCM:ONVO

US$6.6m

OTCPK:APTX

US$6.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Recent updates

Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Price target increased to US$15.00

Alzamend Neuro, Inc. Announces CFO Changes

Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro Receives Non-Compliance Notice from Nasdaq

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

No independent directors

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Director recently sold US$57k worth of stock

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease